Smartkarma AI Primers, Smartkarma

αSK Primers

Smartkarma AI Primers

Smartkarma

Smartkarma unites the fragmented investment industry, connecting institutional investors, independent research providers, and corporates within a single network.

Research Reinvented

Equity Bottom-Up

<ul>
  <li>
<a href="https://smartkarma.com/entities/revolution-medicines-inc">Revolution Medicines</a> is a clinical-stage oncology company at the forefront of developing novel inhibitors for RAS-addicted cancers, a set of mutations that account for approximately 30% of all human cancers.</li>
  <li>The company's key innovation is its 'tri-complex' platform that targets the active, GTP-bound state of RAS proteins (RAS(ON)), a historically 'undruggable' target. This approach is distinct from first-generation inhibitors that target the inactive RAS(OFF) state.</li>
  <li>The lead pipeline asset, daraxonrasib (RMC-6236), is a multi-selective RAS(ON) inhibitor with broad potential across various RAS-mutated cancers, including pancreatic, lung, and colorectal. The FDA has accepted its New Drug Application for previously treated metastatic pancreatic cancer.</li>
</ul><p><em>This content is AI-generated and displayed for general informational purposes only. Please verify independently before use.</em></p>


  
Revolution Medicines is a clinical-stage oncology company at the forefront of developing novel inhibitors for RAS-addicted cancers, a set of mutations that account for approximately 30% of all human cancers.
  The company's key innovation is its 'tri-complex' platform that targets the active, GTP-bound state of RAS proteins (RAS(ON)), a historically 'undruggable' target. This approach is distinct from first-generation inhibitors that target the inactive RAS(OFF) state.
  The lead pipeline asset, daraxonrasib (RMC-6236), is a multi-selective RAS(ON) inhibitor with broad potential across various RAS-mutated cancers, including pancreatic, lung, and colorectal. The FDA has accepted its New Drug Application for previously treated metastatic pancreatic cancer.
This content is AI-generated and displayed for general informational purposes only. Please verify independently before use.

Primer: Revolution Medicines (RVMD US) - Aug 2026

United States

Revolution Medicines, Inc. operates as an oncology company. The Company discovers novel targeted therapies to inhibit elusive frontier targets within notorious growth and survival pathways. Revolution Medicines serves customers worldwide.

Price Gauge
52-week Range	0.00 - 0.00
Market Cap (USDm)	0.00
P/E	0.00
Dividend (Yield)	0.00

Primer: Revolution Medicines (RVMD US) - Aug 2026

Revolution Medicines is a clinical-stage oncology company at the forefront of developing novel inhibitors for RAS-addicted cancers, a set of...

αSK Primers